DeZwarteRidder schreef op 21 januari 2014 22:37:
[...]
Ik ben geen 'basher', dus hoef ik de cijfers van Pharming niet te kennen, maar hier zijn ze:
------------------------------------------------------------------
Leiden, The Netherlands, 7 November 2013. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today published its financial report for the first nine months of 2013.
FINANCIAL HIGHLIGHTS
Revenues and other income increased to €6.0 million (9M 2012: €2.4 million), mainly as a result of a US$ 5 million (€3.8 million) milestone payment by our US partner Santarus on the receipt of FDA acceptance for review of the BLA for Ruconest;
Operating costs from continuing operations decreased to €9.3 million (9M 2012: €17.9 million), driven by reductions following the 2012 restructuring and lowering of project costs regarding Ruconest®;
Financial income and expenses increased to €7.4 million (9M 2012: €5.5 million), primarily as a result of non-cash financial costs relating to the January 2013 €16.35 million convertible bond (2012 costs mainly related to the €8.0 million 2012 convertible bond);
The net loss decreased to €11.1 million (9M 2012 €24.2 million), including the €7.4 million (9M 2012: €5.5 million) of net financing loss;
Net cash outflows from operations decreased to €7.1 million (9M 2012: €11.6 million) while net cash inflows from financing activities amounted to €14.2 million (including €16.0 million from the issue of convertible bonds) and net cash inflows from investing activities amounted to €0.2 million received upon transfer of an intangible fixed asset;
Cash at the end of the third quarter of 2013 amounted to €13.5 million (2012 FY: €6.3 million). The negative equity position decreased to €1.6 million from €7.7 million at year end 2012;
Post events: On 1 October, the Company re-deeemed the final tranche (€2.35 million) of the January 2013 Convertible Bond in cash. On 9 October the Company announced a €12.0 million private placement with institutional investors. As a result of this private placement, Pharming’s equity position has become positive again for the first time since December 2011;
A reverse share split 10:1 was approved at the EGM of 28 February 2013. The total number of shares as of today, 7 November 2013 is 332,434,319.